Myeloproliferative Neoplasms Clinical Trial
A Safety and Tolerability Study of Jaktinib
Summary
This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.
Full Description
This study is a Phase 1, single-arm, open-label, dose escalation trial, to evaluate the safety and tolerability of Jaktinib in patients with PMF or Post-PV/ET MF and who are relapsed/refractory to a marketed JAK inhibitor
Eligibility Criteria
Inclusion Criteria:
Diagnosis of myelofibrosis (primary, post-polycythemia vera, or post-essential thrombocythemia).
Relapsed/refractory to a marketed (FDA approved) JAK inhibitor.
At least 18 years of age.
ECOG PS 0, 1, or 2.
Expected life expectancy is greater than 24 weeks.
Exclusion Criteria:
Any chemotherapy, immunomodulatory therapy, immunosuppressive therapy, corticosteroids, or growth factor treatment within 14 days prior to initiation of study drug.
Major surgery or radiation therapy within 28 days prior to initiation of study drug.
With suspected allergies to jaktinib or its excipient.
Another clinical trial of a new drug or medical instrument within 3 months before screening.
Females who are pregnant, currently breastfeeding, planning to become pregnant.
Unable to adopt effective contraceptive methods during the study.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
How clear is this clinincal trial information?